EGFR and neoplasm: Clinically actionable PIK3CA mutations in exons 9 and 20 have been previously found in the EGFR-mutant tumours of patients with acquired resistance to first- and second-generation EGFR-TKIs5,28–30 and could have been selected as a result of TKI selective pressure.